CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Budapest, Hungary and 374 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Tatabánya, Hungary and 39 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Budapest, Hungary and 226 other locations
after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...
Phase 2
Budapest, Hungary and 121 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Budapest, Hungary and 506 other locations
with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who car...
Phase 3
Budapest, Hungary and 77 other locations
III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...
Phase 3
Budapest, Hungary and 258 other locations
with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of ...
Phase 1, Phase 2
Törökbálint, Hungary and 56 other locations
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Phase 1, Phase 2
Budapest, Hungary and 114 other locations
receptor-low/HER2-negative breast cancer....
Phase 3
Budapest, Hungary and 282 other locations
Clinical trials
Research sites
Resources
Legal